tizetatug rezetecan (SHR-A1921) / Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tizetatug rezetecan (SHR-A1921) / Jiangsu Hengrui Pharma
SHR-A1921-303, NCT06394492: SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Recruiting
3
440
RoW
SHR-A1921, Doxorubicin, Paclitaxel, Topotecan
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Ovarian Cancer
05/26
12/26
SHR-A1921-301, NCT06211023: A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

Not yet recruiting
2/3
520
NA
SHR-1921, carboplatin, platinum-based doublet chemotherapy
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Ovarian Cancer
06/26
06/26
NCT06145308: Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Recruiting
2
10
RoW
Vedolizumab, larotinib or enttraitinib, antiandrogen drug treatment, leprerelin + bicalutamide ± Abiraterone 1000mg po qd, ESG401, small molecule multi-target tyrosine kinase inhibitors± Chemioterapy, apatinib or erlotinib, albumin paclitaxel with platinum, HR-positive group, PI3K mutant group, Homologous Recombination repair defect group, Nectin-4 ADC group, Ivoximab group, Apalolito vorellizumab group
Peking Union Medical College, Peking University Hospital of Stomatology
Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy
07/26
07/26
NCT06210438: SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

Not yet recruiting
2
24
RoW
SHR-A1921 + Bevacizumab
Fudan University
TNBC, Brain Metastasis
06/25
06/26
NCT06465238: Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

Not yet recruiting
2
30
RoW
SHR-A2009, SHR-A1921
Henan Cancer Hospital
NSCLC
06/26
06/27
NCT06433609: Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Not yet recruiting
2
131
RoW
SHR-A1811, SHR-A1921, Adebrelimab
Beijing GoBroad Hospital
Advanced Breast Cancer
07/27
11/27
NCT06480136: SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment

Not yet recruiting
2
32
NA
SHR-A1921 injection and adebrelimab injection
Shanghai Pulmonary Hospital, Shanghai, China
NSCLC
06/27
02/28
FASCINATE-N, NCT05582499: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting
2
716
RoW
Dalpiciclib, SHR-6390, Pyrotinib, SHR-A1811, SHR-1316, Camrelizumab, SHR-1210, SHR-A1921, Pertuzumab, Trastuzumab, Goserelin, Letrozole, Nab paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide, Fluzoparib, SHR-3162, Apatinib, Famitinib
Fudan University
Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/24
09/25
NCT06649331: Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Recruiting
2
120
RoW
SHR-A1811, SHR-A1921, SHR-A2009, SHR-A2102
Fudan University
Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast Cancer
09/26
09/27
NCT06470672: Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Not yet recruiting
2
32
RoW
SHR-A1921, Adebrelimab
Fudan University
Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
03/26
07/26
NCT05924256: A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Recruiting
2
88
RoW
SHR-A1811, SHR 3680 + leuprolide, SHR-A1921
Fudan University
Advanced Salivary Gland Carcinoma
09/25
09/26
BCTOP-L-M05, NCT05594095: SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting
2
620
RoW
PIK3CA inhibitor, AKT inhibitor, Carrelizumab, SHR1210, Famitinib, Fluzoparib, SHR3162, Dalpiciclib, SHR6390, SHR-A1811, Everolimus, Aromatase Inhibitors or Fulvestrant, Goserelin, TPC, Sorafenib, Apatinib, SHR-A1921, SHR-A2102, SHR-A2009, SHR-1167, SHR-6209, bevacizumab
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University, Nanchang People's Hospital, Liaoning Cancer Hospital & Institute, The Affiliated Hospital of Nantong University, The First Hospital of Jilin University
Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
12/25
12/26
ChiCTR2400086362: An exploratory clinical study of SHR-A1921 combined with adebrelimab in the treatment of advanced NSCLC who failed the previous standard first-line treatment

Not yet recruiting
2
32
 
SHR-A1921+adebrelimab
shanghai pulmonary hospital; shanghai pulmonary hospital, Shanghai Pulmonary Hospital
Non-Small Cell Lung Cancer
 
 
ChiCTR2400087339: The conversion therapy for the stage III unresectable non-small cell lung cancer: a patient-oriented, prospective, open-label, multicentric, umbrella, phase II clinical trial

Recruiting
2
165
 
Befotertinib; Iruplinalkib/Ensartinib/Bozitinib; Toripalimab+chemotherapy; Adebrelimab+SHR-A1921
Shanghai Chest Hospital; Shanghai Chest Hospital, Self-raised
Stage III unresectable non-small cell lung cancer
 
 
SHR-A1921-205, NCT06434103: Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

Not yet recruiting
1/2
124
NA
SHR-A1921；Adebrelimab；SHR-8068；carboplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Non-small Cell Lung Cancer
06/25
03/27
NCT06474455: A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
156
RoW
SHR-9839 ；SHR-A2009, SHR-9839 ； SHR-A1921, SHR-9839 ； pemetrexed ；carboplatin, SHR-9839 ； Almonertinib
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
06/26
06/27
NCT06385678: A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Enrolling by invitation
1/2
70
RoW
HRS-4642, Adebrelimab, SHR-9839, Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection, Cetuximab Solution for Infusion
Jiangsu HengRui Medicine Co., Ltd.
Advanced KRAS G12D Mutant Solid Tumors
10/25
08/26
SHR-A1921-201, NCT05765032: Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
220
RoW
SHR-A1921；
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumor
04/25
02/26
SHR-A1921-I-102-AUS, NCT05594875: A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors

Completed
1
9
RoW
SHR-1921
Atridia Pty Ltd.
Advanced Solid Tumor
04/24
04/24
SHR-A1921-I-101, NCT05154604: A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours

Not yet recruiting
1
156
NA
SHR-A1921
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumours
08/24
08/24
ChiCTR2400084245: An exploratory study of SHR-A1921 combined with S-1 for patients with advanced pancreatic cancer

Not yet recruiting
N/A
45
 
SHR-A1921 combined with S-1
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, The research drug SHR-A1921 was provided by Jjiangsu Hengrui Medicine Co.,ltd.
pancreatic cancer
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tizetatug rezetecan (SHR-A1921) / Jiangsu Hengrui Pharma
SHR-A1921-303, NCT06394492: SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Recruiting
3
440
RoW
SHR-A1921, Doxorubicin, Paclitaxel, Topotecan
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Ovarian Cancer
05/26
12/26
SHR-A1921-301, NCT06211023: A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

Not yet recruiting
2/3
520
NA
SHR-1921, carboplatin, platinum-based doublet chemotherapy
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Ovarian Cancer
06/26
06/26
NCT06145308: Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Recruiting
2
10
RoW
Vedolizumab, larotinib or enttraitinib, antiandrogen drug treatment, leprerelin + bicalutamide ± Abiraterone 1000mg po qd, ESG401, small molecule multi-target tyrosine kinase inhibitors± Chemioterapy, apatinib or erlotinib, albumin paclitaxel with platinum, HR-positive group, PI3K mutant group, Homologous Recombination repair defect group, Nectin-4 ADC group, Ivoximab group, Apalolito vorellizumab group
Peking Union Medical College, Peking University Hospital of Stomatology
Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy
07/26
07/26
NCT06210438: SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

Not yet recruiting
2
24
RoW
SHR-A1921 + Bevacizumab
Fudan University
TNBC, Brain Metastasis
06/25
06/26
NCT06465238: Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

Not yet recruiting
2
30
RoW
SHR-A2009, SHR-A1921
Henan Cancer Hospital
NSCLC
06/26
06/27
NCT06433609: Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Not yet recruiting
2
131
RoW
SHR-A1811, SHR-A1921, Adebrelimab
Beijing GoBroad Hospital
Advanced Breast Cancer
07/27
11/27
NCT06480136: SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment

Not yet recruiting
2
32
NA
SHR-A1921 injection and adebrelimab injection
Shanghai Pulmonary Hospital, Shanghai, China
NSCLC
06/27
02/28
FASCINATE-N, NCT05582499: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting
2
716
RoW
Dalpiciclib, SHR-6390, Pyrotinib, SHR-A1811, SHR-1316, Camrelizumab, SHR-1210, SHR-A1921, Pertuzumab, Trastuzumab, Goserelin, Letrozole, Nab paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide, Fluzoparib, SHR-3162, Apatinib, Famitinib
Fudan University
Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/24
09/25
NCT06649331: Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Recruiting
2
120
RoW
SHR-A1811, SHR-A1921, SHR-A2009, SHR-A2102
Fudan University
Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast Cancer
09/26
09/27
NCT06470672: Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Not yet recruiting
2
32
RoW
SHR-A1921, Adebrelimab
Fudan University
Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
03/26
07/26
NCT05924256: A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Recruiting
2
88
RoW
SHR-A1811, SHR 3680 + leuprolide, SHR-A1921
Fudan University
Advanced Salivary Gland Carcinoma
09/25
09/26
BCTOP-L-M05, NCT05594095: SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting
2
620
RoW
PIK3CA inhibitor, AKT inhibitor, Carrelizumab, SHR1210, Famitinib, Fluzoparib, SHR3162, Dalpiciclib, SHR6390, SHR-A1811, Everolimus, Aromatase Inhibitors or Fulvestrant, Goserelin, TPC, Sorafenib, Apatinib, SHR-A1921, SHR-A2102, SHR-A2009, SHR-1167, SHR-6209, bevacizumab
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University, Nanchang People's Hospital, Liaoning Cancer Hospital & Institute, The Affiliated Hospital of Nantong University, The First Hospital of Jilin University
Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
12/25
12/26
ChiCTR2400086362: An exploratory clinical study of SHR-A1921 combined with adebrelimab in the treatment of advanced NSCLC who failed the previous standard first-line treatment

Not yet recruiting
2
32
 
SHR-A1921+adebrelimab
shanghai pulmonary hospital; shanghai pulmonary hospital, Shanghai Pulmonary Hospital
Non-Small Cell Lung Cancer
 
 
ChiCTR2400087339: The conversion therapy for the stage III unresectable non-small cell lung cancer: a patient-oriented, prospective, open-label, multicentric, umbrella, phase II clinical trial

Recruiting
2
165
 
Befotertinib; Iruplinalkib/Ensartinib/Bozitinib; Toripalimab+chemotherapy; Adebrelimab+SHR-A1921
Shanghai Chest Hospital; Shanghai Chest Hospital, Self-raised
Stage III unresectable non-small cell lung cancer
 
 
SHR-A1921-205, NCT06434103: Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

Not yet recruiting
1/2
124
NA
SHR-A1921；Adebrelimab；SHR-8068；carboplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Non-small Cell Lung Cancer
06/25
03/27
NCT06474455: A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
156
RoW
SHR-9839 ；SHR-A2009, SHR-9839 ； SHR-A1921, SHR-9839 ； pemetrexed ；carboplatin, SHR-9839 ； Almonertinib
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
06/26
06/27
NCT06385678: A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Enrolling by invitation
1/2
70
RoW
HRS-4642, Adebrelimab, SHR-9839, Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection, Cetuximab Solution for Infusion
Jiangsu HengRui Medicine Co., Ltd.
Advanced KRAS G12D Mutant Solid Tumors
10/25
08/26
SHR-A1921-201, NCT05765032: Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
220
RoW
SHR-A1921；
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumor
04/25
02/26
SHR-A1921-I-102-AUS, NCT05594875: A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors

Completed
1
9
RoW
SHR-1921
Atridia Pty Ltd.
Advanced Solid Tumor
04/24
04/24
SHR-A1921-I-101, NCT05154604: A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours

Not yet recruiting
1
156
NA
SHR-A1921
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumours
08/24
08/24
ChiCTR2400084245: An exploratory study of SHR-A1921 combined with S-1 for patients with advanced pancreatic cancer

Not yet recruiting
N/A
45
 
SHR-A1921 combined with S-1
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, The research drug SHR-A1921 was provided by Jjiangsu Hengrui Medicine Co.,ltd.
pancreatic cancer
 
 

Download Options